CGEM
Cullinan Therapeutics, Inc.
$14.55
-1.15%
2026-05-08
About Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-5.38
EPS (TTM)
$-3.37
ROE
-48.2%
Profit Margin
0.0%
Debt/Equity
0.65
Price/Book
2.53
Beta
-0.10
Market Cap
$925.8M
Avg Volume (10D)
870K
Recent Breakout Signals
No recent breakout signals detected for CGEM.
Recent Price Range (60 Days)
60D High
$16.74
60D Low
$11.40
Avg Volume
797K
Latest Close
$14.55
Get breakout alerts for CGEM
Sign up for Breakout Scanner to receive daily notifications when CGEM triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Cullinan Therapeutics, Inc. (CGEM) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CGEM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CGEM operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.